44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.
41 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This study found that diphenylcyclopropenone therapy resulted in over 50% hair regrowth in 71% of alopecia totalis patients, with a significant relapse association with thyroid disease, suggesting treatment could be viable but should continue for at least two years.
36 citations
,
May 2005 in “BMC dermatology” This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.
21 citations
,
June 2017 in “Journal of The American Academy of Dermatology” This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.
20 citations
,
June 2019 in “Archives of dermatological research” In this study, combination therapy with DPCP and anthralin promoted hair regrowth in 40.62% of alopecia areata patients who were unresponsive to DPCP alone, with response improving over longer treatment durations.
19 citations
,
October 2015 in “British Journal of Dermatology” This review reports very low quality evidence for the effectiveness and safety of treatments in extensive resistant alopecia areata and emphasizes the need for high-quality randomized controlled trials.
17 citations
,
October 2011 in “International Journal of Immunopathology and Pharmacology” This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.
16 citations
,
April 2000 in “Contact dermatitis” In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.
16 citations
,
January 1995 in “Dermatology” This case report discusses chronic mucocutaneous candidiasis with autoimmune and immune deficiencies in candidiasis-endocrinopathy syndrome, noting associated alopecia areata, ineffective topical immunotherapy, and asplenia.
14 citations
,
August 2014 in “Journal of the American Academy of Dermatology” This study found that topical diphenylcyclopropenone is an effective treatment for extensive alopecia areata, with significant hair regrowth reported in most patients, though effectiveness varied with disease characteristics.
10 citations
,
June 2019 in “Dermatologic therapy” In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.
10 citations
,
January 2018 in “Postępy Dermatologii i Alergologii” This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.
10 citations
,
January 2010 in “Acta dermato-venereologica” Light therapy can effectively treat vitiligo and hair loss caused by a specific medication.
9 citations
,
April 2016 in “Australasian journal of dermatology” This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.
8 citations
,
January 2018 in “Journal of the American Academy of Dermatology” This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.
5 citations
,
January 2014 in “Hospital pharmacy” This case report suggests that frequent application of diphenylcyclopropenone 2% solution to the scalp for alopecia areata may lead to scalp angioedema.
4 citations
,
August 2013 in “Case reports in dermatology” This case report describes a patient in whom vitiligo was induced by diphenylcyclopropenone treatment for alopecia universalis, highlighting the potential overlap of susceptibility genes between the two conditions.
3 citations
,
April 2024 in “JAAD Case Reports” This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.
3 citations
,
July 2023 in “International Journal of Trichology” This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.
3 citations
,
November 2021 in “Skin Appendage Disorders” This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.
2 citations
,
May 2024 in “International Journal of Dermatology” 2 citations
,
May 2024 in “International Journal of Medical Arts” This study found that topical DPCP was more effective for hair regrowth in resistant alopecia areata compared to anthralin, with both treatments having similar safety profiles.
2 citations
,
January 1999 in “Dermatology” 1 citations
,
August 2024 in “Skin Health and Disease” Among pediatric alopecia areata patients treated with DPCP, this study reported complete hair regrowth in 8.8% and any regrowth in 61.8% after one year, with better outcomes for those with milder initial symptoms and longer treatment durations.
1 citations
,
August 2024 in “Journal of Pharmacy & Pharmaceutical Sciences” This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.
1 citations
,
February 2023 in “Deleted Journal” This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.
1 citations
,
January 2017 in “International journal of trichology” This case report suggests that topical diphenylcyclopropenone (DPCP) may be beneficial for treating both alopecia areata and verruca vulgaris, although it is not typically a first-line therapy.
January 2021 in “Online Publication Service of Würzburg University (Würzburg University)” This study examines the use of diphenylcyclopropenone in treating alopecia areata patients at the University Hospital Würzburg and investigates how the treatment affects patients' quality of life.
January 2005 in “Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München)” This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.
January 2025 in “International Journal of Trichology” This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.